Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Pacira BioSciences, Inc.PCRX · Entity 4928 | Senior Vice President, Finance | October 08, 2026 | October 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Pacira BioSciences, Inc.
Report date October 08, 2026 · Filed October 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 62,284.242 |
Ending reported balance
After 2026-10-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-08 · Exercise / conversion · Acquired 6,000 · Balance 68,284.242 F1: The option exercise and sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on March 12, 2026. Row 2 · 2026-10-08 · Sale · Disposed 6,000 · Balance 62,284.242 F1: The option exercise and sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on March 12, 2026. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.35 · Expires 2026-12-07 | Direct | 0 |
Reported balance
After 2026-10-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-08 · Exercise / conversion · Disposed 6,000 · Balance 0 F1: The option exercise and sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on March 12, 2026. F2: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vested as to the remaining shares in successive equal quarterly installments over the subsequent three years. |
Filing footnotes · ownership attribution and instrument terms
F1: The option exercise and sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on March 12, 2026.
F2: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vested as to the remaining shares in successive equal quarterly installments over the subsequent three years.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2019 Filed Jun 12, 2019 21:12 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 2,126 | $44.28 | $94,139.28 |
DisclosureSEC source: 0001209191-19-036448 · doc4.xml · nonDerivative · entry 1 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,042 Read SEC document |
| June 05, 2019 Filed Jun 6, 2019 20:58 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 11,200 | $0.00 Strike: $43.54 | $0.00 |
DisclosureSEC source: 0001209191-19-035123 · doc4.xml · derivative · entry 3 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,200 Underlying: Common Stock · 11,200 shares Expires 2029-06-05 F4 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| June 05, 2019 Filed Jun 6, 2019 20:58 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 1,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-035123 · doc4.xml · nonDerivative · entry 2 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,168 F3 · shares: Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2020, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| June 04, 2019 Filed Jun 6, 2019 20:58 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 967 | $42.91 | $41,493.97 |
DisclosureSEC source: 0001209191-19-035123 · doc4.xml · nonDerivative · entry 1 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,268 F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. F2 · balance_after: Includes 761 shares of common stock acquired under the issuer's employee stock purchase plan in December 2018. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 21:25 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $10.34 | $0.00 |
DisclosureSEC source: 0001209191-18-057394 · doc4.xml · derivative · entry 3 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 1,000 shares Expires 2021-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested and became exercisable as to 25% of the option shares on May 2, 2012 and vested as to the remaining shares in successive equal monthly installments over the subsequent 36 months. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 21:25 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 1,000 | $54.35 | $54,350.00 |
DisclosureSEC source: 0001209191-18-057394 · doc4.xml · nonDerivative · entry 2 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,474 F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 21:25 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 1,000 | $10.34 | $10,340.00 |
DisclosureSEC source: 0001209191-18-057394 · doc4.xml · nonDerivative · entry 1 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,474 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| September 24, 2018 Filed Sep 26, 2018 21:13 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $10.34 | $0.00 |
DisclosureSEC source: 0001209191-18-052315 · doc4.xml · derivative · entry 3 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 1,000 shares Expires 2021-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested and became exercisable as to 25% of the option shares on May 2, 2012 and vested as to the remaining shares in successive equal monthly installments over the subsequent 36 months. Read SEC document |
| September 24, 2018 Filed Sep 26, 2018 21:13 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 1,000 | $50.70 | $50,700.00 |
DisclosureSEC source: 0001209191-18-052315 · doc4.xml · nonDerivative · entry 2 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,474 F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| September 24, 2018 Filed Sep 26, 2018 21:13 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 1,000 | $10.34 | $10,340.00 |
DisclosureSEC source: 0001209191-18-052315 · doc4.xml · nonDerivative · entry 1 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,474 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| August 22, 2018 Filed Aug 24, 2018 20:59 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 1,667 | $44.48 | $74,148.16 |
DisclosureSEC source: 0001209191-18-048389 · doc4.xml · nonDerivative · entry 1 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,474 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.35 to $44.60, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 23:20 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $38.35 | $0.00 |
DisclosureSEC source: 0001209191-18-038201 · doc4.xml · derivative · entry 2 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-06-13 F2 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 23:20 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-038201 · doc4.xml · nonDerivative · entry 1 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,141 F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2019, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| June 04, 2018 Filed Jun 7, 2018 00:09 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 801 | $33.02 | $26,449.02 |
DisclosureSEC source: 0001209191-18-036183 · doc4.xml · nonDerivative · entry 1 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,641 F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. Read SEC document |
| December 15, 2017 Filed Dec 19, 2017 00:52 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 340 | $43.70 | $14,858.00 |
DisclosureSEC source: 0001209191-17-066234 · doc4.xml · nonDerivative · entry 1 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,442 F1 · balance_after: Includes 719 shares of common stock acquired under the issuer's employee stock purchase plan in June 2017. Read SEC document |
| June 14, 2017 Filed Jun 17, 2017 00:05 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $44.20 | $0.00 |
DisclosureSEC source: 0001209191-17-040681 · doc4.xml · derivative · entry 2 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2027-06-14 F2 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| June 14, 2017 Filed Jun 17, 2017 00:05 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-040681 · doc4.xml · nonDerivative · entry 1 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,063 F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2018, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| June 07, 2017 Filed Jun 9, 2017 23:08 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 1,119 | $44.37 | $49,650.03 |
DisclosureSEC source: 0001209191-17-039011 · doc4.xml · nonDerivative · entry 1 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,063 Read SEC document |
| June 05, 2017 Filed Jun 7, 2017 22:59 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 601 | $43.32 | $26,035.92 |
DisclosureSEC source: 0001209191-17-038418 · doc4.xml · nonDerivative · entry 1 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,182 F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. F2 · balance_after: Includes 330 shares of common stock acquired under the issuer's employee stock purchase plan in June 2016. Read SEC document |
| December 07, 2016 Filed Dec 10, 2016 01:24 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $32.35 | $0.00 |
DisclosureSEC source: 0001209191-16-154557 · doc4.xml · derivative · entry 1 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2026-12-07 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.